PON1 and Alzheimer disease: For example, oxLDL, paraoxonase, arylesterase, and lactonase activities of PON1 and PAF-AH activity were quantified in serum from AD patients (n = 49, 74-year-olds, 41% male, MMSE score = 21 ± 5) and age- and sex-matched control individuals (n = 34) [87] as well as cognition (MMSE score), PON1 activities were significantly reduced (by 22–29%) and oxLDL was significantly increased (by 28%) in AD patients vs. controls; PAF-AH was also elevated (by 45%).